eFFECTOR Therapeutics reports positive interim results in zotatifin (EFT226) Ph1/2 clinical trial

Clinical Impact

Jun 5

Written By Frances Benson

https://investors.effector.com/news-releases/news-release-details/effector-therapeutics-reports-positive-interim-results-zotatifin

2022

Frances Benson

Mineralys Therapeutics raises $118M in Series B

Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial